Search hospitals > Nebraska > Bellevue
Nebraska Medicine-Bellevue
Claim this profileBellevue, Nebraska 68123
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Breast cancer
Conducts research for Lung Cancer
Conducts research for Bladder Cancer
73 reported clinical trials
22 medical researchers
Summary
Nebraska Medicine-Bellevue is a medical facility located in Bellevue, Nebraska. This center is recognized for care of Breast Cancer, Cancer, Breast cancer, Lung Cancer, Bladder Cancer and other specialties. Nebraska Medicine-Bellevue is involved with conducting 73 clinical trials across 181 conditions. There are 22 research doctors associated with this hospital, such as Jill C. Beck, Matthew Lunning, DO, Jairam Krishnamurthy, MD, and Sarah Holstein.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
2Cancer
Global LeaderStage IV
Stage III
BCR/ABL negative
Top PIs
Jill C. BeckChildren's Hospital and Medical Center of Omaha5 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
54 reported clinical trials
110 drugs studied
Matthew Lunning, DOUniversity of Nebraska Medical Center8 years of reported clinical research
Studies Non-Hodgkin's Lymphoma
Studies Diffuse Large B-Cell Lymphoma
13 reported clinical trials
40 drugs studied
Jairam Krishnamurthy, MDUniversity of Nebraska Medical Center2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
11 reported clinical trials
26 drugs studied
Sarah HolsteinUniversity of Nebraska Medical Center1 year of reported clinical research
Studies Multiple Myeloma
Studies Immune Dysfunction
9 reported clinical trials
17 drugs studied
Clinical Trials running at Nebraska Medicine-Bellevue
Skin Cancer
Bladder Cancer
Breast Cancer
Lung Cancer
Cancer
Kidney Cancer
Breast cancer
Esophageal cancer
Prostate Cancer
Bladder Carcinoma
Cemiplimab + Surgery
for Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting2 awards Phase 37 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Gabapentin
for Pain in Head and Neck Cancer
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region
Recruiting1 award Phase 314 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Nebraska Medicine-Bellevue?
Nebraska Medicine-Bellevue is a medical facility located in Bellevue, Nebraska. This center is recognized for care of Breast Cancer, Cancer, Breast cancer, Lung Cancer, Bladder Cancer and other specialties. Nebraska Medicine-Bellevue is involved with conducting 73 clinical trials across 181 conditions. There are 22 research doctors associated with this hospital, such as Jill C. Beck, Matthew Lunning, DO, Jairam Krishnamurthy, MD, and Sarah Holstein.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.